Clinical Trial Update: Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)

View source ↗

Summary

A clinical trial evaluating Symbicort Turbuhaler (budesonide/formoterol) in chronic obstructive pulmonary disease has completed. The sponsor is AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Symbicort Turbuhaler (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Status: COMPLETED